Mitchell, Eleanor JAhmed, KhaledBreeman, SuzanneCotton, SeonaidhConstable, LyndaFerry, GillianGoodman , KirsteenHickey, HelenMeakin, GarryMironov, KatyQuann, NiamhWakefield, NatalieMcDonald, Alison2020-09-152020-09-152020-09-11Mitchell, E J, Ahmed, K, Breeman, S, Cotton, S, Constable, L, Ferry, G, Goodman , K, Hickey, H, Meakin, G, Mironov, K, Quann, N, Wakefield, N & McDonald, A 2020, 'It is unprecedented : trial management during the COVID-19 pandemic and beyond', Trials, vol. 21, 784, pp. 784. https://doi.org/10.1186/s13063-020-04711-61745-6215ORCID: /0000-0001-9646-3904/work/93483378https://hdl.handle.net/2164/15134Funding: UKTMN is funded by the Nuffield Department of Population Health (NDPH) at the University of Oxford. Acknowledgments: We thank Graeme MacLennan, Director of the Centre for Health Care Randomised Trials (CHaRT) for the inspiration for this article and UKTMN members for their input into its content. We also thank the huge clinical trial community, both nationally and internationally, for continuing to run clinical trials in these challenging times, and for regulatory agencies to adapting their processes to enable efficiencies.7522498engCOVID-19pandemicclinical trialTrial managementClinical trialPandemicBetacoronavirus/pathogenicityPandemicsData AccuracyRisk AssessmentHumansRisk FactorsWorkflowData CollectionCoronavirus Infections/diagnosisHost-Pathogen InteractionsClinical Trials Data Monitoring CommitteesTime FactorsPatient SafetyClinical Trials as Topic/methodsResearch DesignPneumonia, Viral/diagnosisR MedicinePharmacology (medical)Medicine (miscellaneous)RJournal article10.1186/s13063-020-04711-6http://www.scopus.com/inward/record.url?scp=85090903048&partnerID=8YFLogxK21